The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Cyclooxygenase-2 and Cancer Treatment: Understanding the Risk Should Be Worth the Reward
Open accessAbstract
Targeting the prostaglandin (PG) pathway is potentially a critical intervention for the prevention and treatment of cancer. Central to PG biosynthesis are two isoforms of cyclooxygenase (COX 1 and 2), which produce prostaglandin H2 (PGH2) from plasma membrane stores of fatty acids. COX-1 is constitutively expressed, whereas COX-2 is an inducible isoform upregulated in many cancers. Differences between COX-1 and COX-2 catalytic sites enabled development of selective inhibitors. Downstream of the COX enzymes, prostaglandin E2 synthase converts available PGH2 to prostaglandin E2 (PGE2), which can stimulate cancer progression. Significant research efforts are helping identify more selective targets and fully elucidate the downstream targets of prostaglandin E2-mediated oncogenesis. Nonetheless, as a key rate-limiting control point of PG biosynthesis, COX-2 continues to be an important anticancer target. As we embark upon a new era of individualized medicine, a better understanding of the individual risk and/or benefit involved in COX-2 selective targeting is rapidly evolving. This review endeavors to summarize developments in our understanding of COX-2 and its downstream targets as vital areas of anticancer research and to provide the current status of an exciting aspect of molecular medicine. Clin Cancer Res; 16(5); 1384–90
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Phospholipase A2 structure/function, mechanism, and signaling
Burke, J. E., & Dennis, E. A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800033-jlr200 · Cited by 933
Acetaminophen: Antipyretic or hypothermic in mice? In either case, PGHS-1b (COX-3) is irrelevant
Li, S., Dou, W., Tang, Y., Goorha, S., Ballou, L. R., & Blatteis, C. M. (2008) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2007.10.007 · Cited by 63
Cited by
Ferulic acid: Pharmacological and toxicological aspects
Mancuso, C., & Santangelo, R. (2014) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.12.024 · Cited by 572
Cancer and Inflammation: An Old Intuition with Rapidly Evolving New Concepts
Trinchieri, G. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075008 · Cited by 511
Li, H.-J., Reinhardt, F., Herschman, H. R., & Weinberg, R. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0101 · Cited by 340
Platelets and cancer: a casual or causal relationship: revisited
Menter, D. G., Tucker, S. C., Kopetz, S., Sood, A. K., Crissman, J. D., & Honn, K. V. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9498-0 · Cited by 316
Self-citationMolecular pathways in cancer-related inflammation
Del Prete, A., Allavena, P., Santoro, G., Fumarulo, R., Corsi, M. M., & Mantovani, A. (2011) · Biochemia Medica · doi:10.11613/bm.2011.036 · Cited by 181
Metadata
- Authors
- Menter, D. G., Schilsky, R. L., & DuBois, R. N.
- Venue
- Clinical Cancer Research
- Published
- 2010-02-28
- Volume
- 16
- Issue
- 5
- Pages
- 1384-1390
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2098570483
- Cited by
- 203
- References
- 3
- FWCI
- 14.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclooxygenase-2 and Cancer Treatment: Understanding the Risk Should Be Worth the Reward. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-0788
- The paper
- Menter, D. G., Schilsky, R. L., & DuBois, R. N. (2010). Cyclooxygenase-2 and Cancer Treatment: Understanding the Risk Should Be Worth the Reward. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-0788
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.